nefopam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   5 Trials   5 Trials   163 News 


«123»
  • ||||||||||  Metapain (nefopam/paracetamol) / Aptys Pharma
    Enrollment open, Trial initiation date:  Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction (clinicaltrials.gov) -  Mar 3, 2021   
    P3,  N=321, Recruiting, 
    Registration: Thai Clinical Trail Registry (TCTR) ID TCTR20181016001; registered on 12 October 2018. Not yet recruiting --> Recruiting | Initiation date: Nov 2020 --> Feb 2020
  • ||||||||||  Neforex (nefopam) / Incepta
    Journal:  Predicting Acute Pain After Surgery: A Multivariate Analysis. (Pubmed Central) -  Feb 20, 2021   
    The presented analysis offers detailed insight into current practice patterns and reveals modifications that can be implemented in today's clinical practice. Our results also suggest that parameters other than those currently studied are relevant for postoperative pain including biological and psychological variables.
  • ||||||||||  Neforex (nefopam) / Incepta
    Journal:  L-Histidinium Chiral Ionic Liquid Functionalized β-Cyclodextrin as Chiral Selector in Capillary Electrophoresis. (Pubmed Central) -  Jan 23, 2021   
    The effect of some key parameters such as chiral selector concentration, buffer pH and applied voltage on the enantioseparation was investigated in detail. In the interest of the chiral discrimination mechanism and the enhanced enantioselectivity of L-HMCDCl, molecular modeling with AutoDock was employed to study the interaction, which was in good agreement with experimental results.
  • ||||||||||  gabapentin / Generic mfg., nefopam / Generic mfg.
    Enrollment open, Trial primary completion date, Surgery:  The Efficacy of Postoperative Analgesia of Gabapentin Plus Nefopam in the Spinal Surgery (clinicaltrials.gov) -  Jan 11, 2021   
    P=N/A,  N=30, Recruiting, 
    Fentanyl PCA with 80 mg of nefopam as an adjuvant did not have a superior analgesic effect after laparoscopic colorectal cancer surgery. Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2020 --> May 2021
  • ||||||||||  nefopam / Generic mfg.
    Enrollment open, Surgery:  Nefopam for Post Video-Assisted Thoracoscopic Lobectomy (clinicaltrials.gov) -  Nov 18, 2020   
    P4,  N=92, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2020 --> May 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Neforex (nefopam) / Incepta
    Preclinical, Journal:  Pharmacologic targeting of β-catenin improves fracture healing in old mice. (Pubmed Central) -  Oct 28, 2020   
    20 month old mice were treated with Nefopam or the tankyrase inhibitor XAV939 after a tibia fracture...XAV939 had a more modest effect on β-catenin protein, colony forming units osteoblastic, and the amount of bone at the fracture site. This data supports the notion that high levels of β-catenin in the early phase of fracture healing in old animals slows osteogenesis, and suggests a pharmacologic approach that targets β-catenin to improve fracture repair in the elderly.
  • ||||||||||  pregabalin / Generic mfg., carbamazepine / Generic mfg.
    Retrospective data, Review, Journal:  Adjuvant Analgesic Use in the Critically Ill: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jul 24, 2020   
    In terms of individual medications, reductions in opioid use were demonstrated with acetaminophen (mean difference, 36.17 mg less; 95% CI, 7.86-64.47 mg less; low certainty), carbamazepine (mean difference, 54.69 mg less; 95% CI, 40.39-to 68.99 mg less; moderate certainty), dexmedetomidine (mean difference, 10.21 mg less; 95% CI, 1.06-19.37 mg less; low certainty), ketamine (mean difference, 36.81 mg less; 95% CI, 27.32-46.30 mg less; low certainty), nefopam (mean difference, 70.89 mg less; 95% CI, 64.46-77.32 mg less; low certainty), nonsteroidal anti-inflammatory drugs (mean difference, 11.07 mg less; 95% CI, 2.7-19.44 mg less; low certainty), and tramadol (mean difference, 22.14 mg less; 95% CI, 6.67-37.61 mg less; moderate certainty). Clinicians should consider using adjunct agents to limit opioid exposure and improve pain scores in critically ill patients.
  • ||||||||||  Neforex (nefopam) / Incepta, vincristine / Generic mfg.
    Preclinical, Journal:  The Antiallodynic Effect of Nefopam on Vincristine-Induced Neuropathy in Mice. (Pubmed Central) -  Mar 1, 2020   
    The concentration of neurokinin-1 receptor was significantly decreased in the Nefopam group (P<0.05). Intraperitoneally administered nefopam yielded a dose-dependent attenuation of mechanical allodynia and decreased neurokinin-1 receptor concentration, suggesting that the neurokinin-1 receptor is involved in the antiallodynic effects of nefopam in vincristine neuropathy.
  • ||||||||||  pregabalin / generics
    Different approaches in pain management of acute low back pain in Emergency Department. () -  Sep 10, 2019 - Abstract #EUSEM2019EUSEM_985;    
    2nd line treatment, designed for patients that didnt benefit from the 1st line, consists from a Lidocaine 1%(3mg/kg) + Ketamine(0.25mg/kg) mixed infusion over two hours...Conclusion There is not yet a defined therapeutic care process for the patient with LBP with clear criteria for an ED visit. Most of the time, different approaches in multimodal pain management may be useful, in complicated chronic sciatic pain the role of pain interventionist is clear.
  • ||||||||||  Valdoxan (agomelatine) / Servier, Novartis, Edronax (reboxetine) / Pfizer, Latuda (lurasidone oral) / Sumitomo Dainippon
    Clinical, Review, Journal:  The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. (Pubmed Central) -  Jun 21, 2019   
    ...The emerging antidepressants are: selective monoamine oxidase inhibitors (MAOIs) such as bifemelane, pirlindole, toloxatone, selegiline, rasagiline and safinamide; serotonin-norepinephrine reuptake inhibitors (SNRIs) such as ansofaxine, nefopam and levomilnacipran; norepinephrine reuptake inhibitors (NRIs) such as Reboxetine, viloxazine, teniloxazine (also known as sulfoxazine or sufoxazine), and atomoxetine; Vilazodone (a serotonin 5-HT autoreceptor partial agonist with serotonin reuptake inhibition [SPARI]); Vortioxetine (a serotonin receptors antagonist with serotonin reuptake inhibition [SARI]); atypical antipsychotics such as olanzapine, quetiapine, risperidone, lurasidone, aripiprazole and brexpiprazole; N-methyl-d-aspartate (NMDA)-glutamatergic neurotransmission system blockers such as ketamine, CP-101,606 (traxoprodil), GLYX-13 (rapastinel), NRX-1074 (Apimostinel) and Riluzole...receptors antagonist [MASSA]) remains a paradoxical agent that doesn't fit into any of the currently available classes of antidepressant agents and its pharmacological properties also deemed it unfit and inappropriate to be classified into another separate novel class of antidepressants contrary to the reports published in previous reference literatures. Lastly, this review remarkably advocates for the incorporation of the atypical antipsychotics and NMDA-glutamatergic ionoceptor blockers as new member classes of the antidepressant agents because of their clinically significant roles in the management of depression disorders.
  • ||||||||||  metoclopramide / generics
    Clinical, Journal, Adverse drug reaction:  Opioid analgesics are the leading cause of adverse drug reactions in the obstetric population in South Korea. (Pubmed Central) -  Jun 14, 2019   
    ADRs most frequently occurred in women aged 25 to 34 years, and the trend of ADR with the 20 most commonly reported medications significantly differed among the age groups (P = .011). In addition, the kind of common causative drugs was different among the age groups.Knowledge of medications and clinical conditions resulting in the highest ADR rates among pregnant women is necessary for medical practitioners to administer proper care.